Organ Preservation Program Using Short-Course Radiation & FOLFOXIRI in Rectal Cancer

Phase 2 Completed 38 enrolled Stanford University

NaSingle-groupOpen-labelTreatment

Summary

The purpose of the research is to evaluate whether both chemotherapy and radiotherapy can lead to higher rates of clinical complete response leading to organ preservation in human subjects with cancer. The objective is to learn if this treatment approach may safely be used as an alternative to the standard treatment for rectal cancer and to know the quality-of-life in these patients.

Timeline

Start: 2020-05-21
Primary completion: 2024-01-17
Completion: 2024-01-17

Publications

Brown E, Fisher GA Jr, Shelton A, Chang DT, Pollom E. Advancing clinical trial equity through integration of telehealth and decentralized treatment. JNCI Cancer Spectr. 2024 Jul 1;8(4):pkae050. doi: 10.1093/jncics/pkae050.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Capecitabine	Small molecule	1000 mg/m2	—
Subject	Irinotecan	Small molecule	165 mg/m2	—
Subject	Leucovorin	Small molecule	400 mg/m2	—
Subject	Oxaliplatin	Small molecule	85 mg/m2	—
Subject	Oxaliplatin	Small molecule	130 mg/m2	—
Subject	fluorouracil	Small molecule	2400 mg/m2	—

Organ Preservation Program Using Short-Course Radiation & FOLFOXIRI in Rectal Cancer

Summary

Timeline

Publications

Drugs

Indications